New Strategies for the Treatment of Phenylketonuria (PKU)

Overview

Journal Metabolites

Publisher MDPI

Date 2014 Nov 7

PMID 25375236

Citations 16

Authors

Pietro Strisciuglio

Daniela Concolino

Affiliations

Soon will be listed here.

Abstract

Phenylketonuria (PKU) was the first inherited metabolic disease in which dietary treatment was found to prevent the disease's clinical features. Treatment of phenylketonuria remains difficult due to progressive decrease in adherence to diet and the presence of neurocognitive defects despite therapy. This review aims to summarize the current literature on new treatment strategies. Additions to treatment include new, more palatable foods based on glycomacropeptide that contains very limited amount of aromatic amino acids, the administration of large neutral amino acids to prevent phenylalanine entry into the brain or tetrahydropterina cofactor capable of increasing residual activity of phenylalanine hydroxylase. Moreover, human trials have recently been performed with subcutaneous administration of phenylalanine ammonia-lyase, and further efforts are underway to develop an oral therapy containing phenylanine ammonia-lyase. Gene therapy also seems to be a promising approach in the near future.

Citing Articles

Protein substitutions as new-generation pharmanutrition approach to managing phenylketonuria.

Keskin F, Sahin T, Capasso R, Agagunduz D Clin Exp Pediatr. 2022; 66(8):320-331.

PMID: 36397260 PMC: 10397997. DOI: 10.3345/cep.2022.00584.

Therapeutic applications of gene editing in chronic liver diseases: an update.

Shin J, Lee J, Jung Y, Kim K, Jeong J, Choi D BMB Rep. 2022; 55(6):251-258.

PMID: 35651324 PMC: 9252892.

Protein Degradation and the Pathologic Basis of Phenylketonuria and Hereditary Tyrosinemia.

Sarodaya N, Suresh B, Kim K, Ramakrishna S Int J Mol Sci. 2020; 21(14).

PMID: 32679806 PMC: 7404301. DOI: 10.3390/ijms21144996.

Genome editing technologies to treat rare liver diseases.

Trevisan M, Masi G, Palu G Transl Gastroenterol Hepatol. 2020; 5:23.

PMID: 32258527 PMC: 7063531. DOI: 10.21037/tgh.2019.10.10.

Strategies to engage lost to follow-up patients with phenylketonuria in the United States: Best practice recommendations.

Beazer J, Breck J, Eggerding C, Gordon P, Hacker S, Thompson A Mol Genet Metab Rep. 2020; 23:100571.

PMID: 32140415 PMC: 7044524. DOI: 10.1016/j.ymgmr.2020.100571.

References

Hoeksma M, Reijngoud D, Pruim J, de Valk H, Paans A, van Spronsen F . Phenylketonuria: High plasma phenylalanine decreases cerebral protein synthesis. Mol Genet Metab. 2009; 96(4):177-82. DOI: 10.1016/j.ymgme.2008.12.019. View

Pey A, Stricher F, Serrano L, Martinez A . Predicted effects of missense mutations on native-state stability account for phenotypic outcome in phenylketonuria, a paradigm of misfolding diseases. Am J Hum Genet. 2007; 81(5):1006-24. PMC: 2265664. DOI: 10.1086/521879. View

Enns G, Millan M . Cell-based therapies for metabolic liver disease. Mol Genet Metab. 2008; 95(1-2):3-10. DOI: 10.1016/j.ymgme.2008.06.001. View

Eavri R, Lorberboum-Galski H . A novel approach for enzyme replacement therapy. The use of phenylalanine hydroxylase-based fusion proteins for the treatment of phenylketonuria. J Biol Chem. 2007; 282(32):23402-9. DOI: 10.1074/jbc.M703367200. View

Sarkissian C, Gamez A . Phenylalanine ammonia lyase, enzyme substitution therapy for phenylketonuria, where are we now?. Mol Genet Metab. 2005; 86 Suppl 1:S22-6. DOI: 10.1016/j.ymgme.2005.06.016. View

Cerone R, Andria G, Giovannini M, Leuzzi V, Riva E, Burlina A . Testing for tetrahydrobiopterin responsiveness in patients with hyperphenylalaninemia due to phenylalanine hydroxylase deficiency. Adv Ther. 2013; 30(3):212-28. DOI: 10.1007/s12325-013-0011-x. View

Scala I, Concolino D, Casa R, Nastasi A, Ungaro C, Paladino S . Long-term follow-up of patients with phenylketonuria treated with tetrahydrobiopterin: a seven years experience. Orphanet J Rare Dis. 2015; 10:14. PMC: 4351928. DOI: 10.1186/s13023-015-0227-8. View

Sarkissian C, Shao Z, Blain F, Peevers R, Su H, Heft R . A different approach to treatment of phenylketonuria: phenylalanine degradation with recombinant phenylalanine ammonia lyase. Proc Natl Acad Sci U S A. 1999; 96(5):2339-44. PMC: 26785. DOI: 10.1073/pnas.96.5.2339. View

Blau N . Sapropterin dihydrochloride for the treatment of hyperphenylalaninemias. Expert Opin Drug Metab Toxicol. 2013; 9(9):1207-18. DOI: 10.1517/17425255.2013.804064. View

10.

Fiege B, Blau N . Assessment of tetrahydrobiopterin (BH4) responsiveness in phenylketonuria. J Pediatr. 2007; 150(6):627-30. DOI: 10.1016/j.jpeds.2007.02.017. View

11.

Gamez A, Wang L, Straub M, Patch M, Stevens R . Toward PKU enzyme replacement therapy: PEGylation with activity retention for three forms of recombinant phenylalanine hydroxylase. Mol Ther. 2004; 9(1):124-9. DOI: 10.1016/j.ymthe.2003.11.002. View

12.

Fiori L, Fiege B, Riva E, Giovannini M . Incidence of BH4-responsiveness in phenylalanine-hydroxylase-deficient Italian patients. Mol Genet Metab. 2005; 86 Suppl 1:S67-74. DOI: 10.1016/j.ymgme.2005.06.017. View

13.

Matalon R, Michals-Matalon K, Bhatia G, Grechanina E, Novikov P, McDonald J . Large neutral amino acids in the treatment of phenylketonuria (PKU). J Inherit Metab Dis. 2006; 29(6):732-8. DOI: 10.1007/s10545-006-0395-8. View

14.

Longo N, Siriwardena K, Feigenbaum A, Dimmock D, Burton B, Stockler S . Long-term developmental progression in infants and young children taking sapropterin for phenylketonuria: a two-year analysis of safety and efficacy. Genet Med. 2014; 17(5):365-73. DOI: 10.1038/gim.2014.109. View

15.

Alexander I, Cunningham S, Logan G, Christodoulou J . Potential of AAV vectors in the treatment of metabolic disease. Gene Ther. 2008; 15(11):831-9. DOI: 10.1038/gt.2008.64. View

16.

Longo N, Harding C, Burton B, Grange D, Vockley J, Wasserstein M . Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial. Lancet. 2014; 384(9937):37-44. PMC: 4447208. DOI: 10.1016/S0140-6736(13)61841-3. View

17.

Harding C, Gibson K . Therapeutic liver repopulation for phenylketonuria. J Inherit Metab Dis. 2010; 33(6):681-7. DOI: 10.1007/s10545-010-9099-1. View

18.

Vajro P, Strisciuglio P, Houssin D, Huault G, Laurent J, Alvarez F . Correction of phenylketonuria after liver transplantation in a child with cirrhosis. N Engl J Med. 1993; 329(5):363. DOI: 10.1056/NEJM199307293290517. View

19.

Strisciuglio P, Concolino D, Moricca M, Rivalta L, Parlato G . Normal serum levels of vitamin B12 and folic acid in children with phenylketonuria. Eur J Pediatr. 1995; 154(10):866. DOI: 10.1007/BF01959802. View

20.

Blau N, Hennermann J, Langenbeck U, Lichter-Konecki U . Diagnosis, classification, and genetics of phenylketonuria and tetrahydrobiopterin (BH4) deficiencies. Mol Genet Metab. 2011; 104 Suppl:S2-9. DOI: 10.1016/j.ymgme.2011.08.017. View